Investment Banking
Exclusive Financial Advisor on Pelthos Therapeutics' Senior Secured Term Loan Facility
January 20, 2026
Oppenheimer & Co. Inc. acted as Exclusive Financial Advisor on Pelthos Therapeutics’ $50.0MM Senior Secured Term Loan Facility
Oppenheimer & Co. Inc. acted as Exclusive Financial Advisor on Pelthos Therapeutics’ (NYSE American: PTHS) (“Pelthos”) $50.0MM Senior Secured Term Loan Facility. Pelthos Therapeutics’ Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, announced it has secured financing from Horizon Technology Finance Corporation (“Horizon”) (NASDAQ: HRZN), an affiliate of Monroe Capital, with an initial funding of $30 million, and up to $20 million to support future growth.
Horizon funded $30 million at closing, with up to an additional $20 million available upon achieving certain milestones. The rate is Prime plus 3.75%, currently 10.50%, paid only on drawn capital. The term is sixty months with amortization beginning at month thirty-six with the ability to begin in month 48, if certain milestones are met and interest only until amortization commences. In connection with the financing, Pelthos issued Horizon warrants to purchase 65,488 shares of its common stock, par value $0.0001 per share, at an exercise price of $27.49 per share. Proceeds from the financing will be used to support the commercialization of ZELSUVMI, launch Xepi and Xeglyze, and for working capital and general corporate purposes.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 8709869.1